anticancer agent

Anticancer agent 3 (Compound 4) is an anticancer agent.

Anticancer agent 110 is an anticancer compound with cytotoxic, antitumor, and antileukemic activity that triggers DNA damage and apoptosis and is used in the study of chronic granulocytic leukemia.

(S)-5-chloro-N-(1-((4-chlorophenyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide has antifungal and tuberculostatic activities.

Anticancer agent 73 is an anticancer agent which potently targets transactivation response(TAR) RNA-binding protein 2 (TRBP) and disrupts the TRBP-Dicer interaction. Anticancer agent 73 suppresses the growth and metastasis of HCC in vitro and in vivo by modulating expression profiles of miRNAome and proteome in HCC cells.

Anticancer agent 46 is a potent anti-cancer agent, showing anti-proliferative activity in cellular assays, with an IC50 of 0.986 μM against MGC803 cells.

Anticancer agent 43 is a potent anticancer agent that induces apoptosis through caspase 3, PARP1, and Bax protein-dependent pathways.Anticancer agent 43 induces DNA damage and can be used in the study of glioblastoma in rats.

Anticanceragent 260 (Compound 3g 4d) is an orally effective anticancer agent that inhibits the proliferation of cancer cells HCT-116, MIA-PaCa2, and MDA-MB231, with IC50 values of 98.7, 81.0, and 77.2 µg mL, respectively. It also promotes ulcer formation and lipid peroxidation, and exhibits anti-inflammatory and analgesic activities.

Anticanceragent 263 (compound 7) is an effective anticancer agent. It binds with the G-quadruplex DNA (G4) sequence 22-mer Pu22 (a c-Myc DNA analog). As a structural modulator, Anticanceragent 263 significantly enhances the formation of protein α-helices and has the capacity to form a supramolecular network. Furthermore, Anticanceragent 263 exhibits no cytotoxicity.

Anticanceragent 257 (compound of formula (I)) is an anticancer agent that regulates Nur77 and Nurr1.

Anticanceragent 266 (Compound 3B) is an anticancer agent that inhibits the proliferation of tumor cells. It has an IC50 of 0.13 μM against the MCF-7 breast cancer cell line.

Anticancer agent 7 (Example 5) is a potent anti-cancer compound with an IC50 value of 5 μM against H1650 lung cancer cells.

Anticancer agent 11 an effective broad-spectrum anticancer agent, exerts its therapeutic potential by suppressing angiogenesis and facilitating the formation of DNA cross-links.

Anticancer agent 15, an anticancer agent, exerts its efficacy by elevating intracellular levels of reactive oxygen species (ROS) and inducing cell death in melanoma cancer cells through necroptosis.

Anticancer agent 13 is a compound derived from dicarboxylic acids and amines, developed for use as an anticancer agent.

Anticancer agent 38 (compound 19) is an aryl-urea compound, and is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC 50 of 5.2 μg mL [1].

Compound 12, also known as Anticancer agent 68, functions as an anti-cancer agent by arresting cells at the G2 M phase and inducing programmed cell death. Moreover, it promotes tumor suppression by activating p53 and PTEN [1].

Anticancer agent 75 has good antiplasmodial activity. Anticancer agent 75 is a potent anticancer agent with cytotoxicity and selectivity in cancer cell lines. The cytotoxicity of Anticancer agent 75 to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard [1].

Anticancer agent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0 G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticancer agent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1].

Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1].

Anticancer agent 29 (Compd E Z-6f) exhibits potent anticancer activity with IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, and 0.396 μM for CDK2, CDK1, CDK4, and CDK6, respectively [1].

Anticancer agent 30 (compound 6f-Z) is a potent 3-arylidene-2-oxindole derivative that acts as a selective CDK2 inhibitor, showing significant anticancer activity and potential as a cancer treatment [1].

Anticancer agent 47 (compound 4j) exhibits potent anticancer properties, demonstrating antiproliferative activities, inducing apoptosis, and causing cell cycle arrest at the G0 G1 phase. Moreover, Anticancer agent 47 has shown significant in vivo antitumor activities [1].

Anticancer agent 37 (compound 18) is a sulfonylurea derivative known for its potent anticancer activity. It efficiently inhibits the growth of HePG2 cells, displaying an IC 50 value of 17.2 μg mL [1].

Anticancer Agent 83, a potent inhibitor of LOX IMVI cell growth, demonstrates anticancer efficacy with a GI50 value of 0.15 mM. It disrupts mitochondrial membrane potential and induces DNA damage, thereby promoting apoptosis in leukemia cells [1].